Kala Pharmaceuticals Completes Sale of EYSUVIS® and INVELTYS® to Alcon Inc by Seini Moimoi | Jul 11, 2022 | Portfolio News
Vera Therapeutics Completes Patient Enrollment in Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy by Seini Moimoi | Jul 6, 2022 | Portfolio News
89bio Announces Closing of its Upsized $94.5 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants by Seini Moimoi | Jul 5, 2022 | Portfolio News
Talaris Therapeutics Provides FREEDOM-1 Phase 3 Clinical Update by Seini Moimoi | Jun 30, 2022 | Portfolio News
WelbeHealth Becomes First Program of All-Inclusive Care for the Elderly (PACE) Provider to Convert to Public Benefit Company Status by Seini Moimoi | Jun 29, 2022 | Portfolio News
89bio Reports Positive Topline Results from ENTRIGUE Phase 2 Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) by Seini Moimoi | Jun 28, 2022 | Portfolio News
IntelyCare Announces 900,000 Enrollments in IntelyEdu, Empowering Nursing Professionals With Affordable, Innovative Access to Continuing Education by Seini Moimoi | Jun 17, 2022 | Portfolio News
Inozyme Pharma Announces Partnership with Rady Children’s Institute for Genomic Medicine to Advance Newborn Screening for Genetic Disease by Seini Moimoi | Jun 16, 2022 | Portfolio News
EY Announces IntelyCare Co-Founders as Entrepreneur Of The Year® 2022 New England Award Winners by Seini Moimoi | Jun 14, 2022 | Portfolio News
Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients by Seini Moimoi | Jun 4, 2022 | Portfolio News
